U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C14H12O3S
Molecular Weight 260.308
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIAPROFENIC ACID

SMILES

CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2

InChI

InChIKey=GUHPRPJDBZHYCJ-UHFFFAOYSA-N
InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula C14H12O3S
Molecular Weight 260.308
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tiaprofenic acid is a non-steroidal, anti-inflammatory, analgesic compound, which nonselectively inhibits cyclooxygenase protein. Tiaprofenic acid was approved in Europe for the symptomatic relief of arthritis, ankylosing spondylitis and other inflammatory-rheumatic disorders as well as the painful conditions after injury.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SURGAM

Approved Use

Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Primary
SURGAM

Approved Use

Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Palliative
SURGAM

Approved Use

Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
22 μg/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
21.9 μg/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
21.3 μg/mL
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
20.7 μg/mL
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.55 mg/L
3 mg/kg single, oral
dose: 3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
7.4 mg/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
7.8 mg/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
11.1 mg/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
8.78 mg/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76.71 μg × h/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
65.53 μg × h/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
77.25 μg × h/mL
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79.6 μg × h/mL
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
35.33 mg × h/L
3 mg/kg single, oral
dose: 3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
37.7 mg × h/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
35.8 mg × h/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
44.3 mg × h/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
39.3 mg × h/L
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.77 h
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.47 h
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.05 h
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.25 h
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.82 h
3 mg/kg single, oral
dose: 3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
2.69 h
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
2 h
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
2.36 h
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
2.35 h
3 mg/kg single, intragastric
dose: 3 mg/kg
route of administration: Intragastric
experiment type: SINGLE
co-administered: THIOPENTAL
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.1%
TIAPROFENIC ACID serum
Homo sapiens
1.5%
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.5%
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TIAPROFENIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3%
TIAPROFENIC ACID plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, ADOLESCENT
Health Status: healthy
Age Group: ADOLESCENT
Sex: F
Food Status: UNKNOWN
Sources:
400 mg 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Chronic interstitial cystitis...
AEs leading to
discontinuation/dose reduction:
Chronic interstitial cystitis (grade 3)
Sources:
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Anorexia, Alkaline phosphatase increased...
Other AEs: Lethargy...
AEs leading to
discontinuation/dose reduction:
Anorexia
Alkaline phosphatase increased
ALT increased
GGT increased
Other AEs:
Lethargy
Sources:
AEs

AEs

AESignificanceDosePopulation
Chronic interstitial cystitis grade 3
Disc. AE
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Lethargy
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
ALT increased Disc. AE
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Alkaline phosphatase increased Disc. AE
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Anorexia Disc. AE
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
GGT increased Disc. AE
300 mg 2 times / day multiple, oral
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Hepatotoxicity to several nonsteroidal anti-inflammatory drugs with diclofenac induced histological changes.
1992 Mar
Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans.
1993 Apr
Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis.
1993 Apr
Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.
1993 Jan
Five cases of photocontact dermatitis due to topical ketoprofen: photopatch testing and cross-reaction study.
2001 Feb
In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes.
2001 Jun
Effects of some nonsteroidal anti-inflammatory drugs on articular cartilage of rats in an experimental model of osteoarthritis.
2001 Mar
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.
2001 May-Jun
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
[Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases].
2001 Oct
The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis.
2001 Oct
Photocontact dermatitis to ketoprofen.
2001 Sep
[Tuberculous osteitis of the malar bone].
2002
Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes.
2002 Aug
Use of the photo-micronucleus assay in Chinese hamster V79 cells to study photochemical genotoxicity.
2002 Aug 26
[Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000].
2002 Jan-Feb
[Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)].
2002 Oct
Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules.
2003 Mar
Evaluation of balhimycin as a chiral selector for enantioresolution by capillary electrophoresis.
2004 Aug
Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.
2004 Aug 2
Vehicle effects on in vitro release of tiaprofenic acid from different topical formulations.
2004 Jul
The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Mycobacterium tuberculosis.
2005
Effects of co-administered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery.
2005 Nov 7
In vitro interactions of captopril with NSAID's.
2006 Jul
Activity and potential role of licofelone in the management of osteoarthritis.
2007
Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review.
2007 Jul
Upper gastrointestinal complications associated with NSAIDs in children.
2007 Mar-Apr
Acute NSAID-related transmural duodenitis and extensive duodenal ulceration.
2007 Nov
The pK(a) Distribution of Drugs: Application to Drug Discovery.
2007 Sep 17
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.
2008
The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.
2008 Apr 1
Direct enantioselective HPLC monitoring of lipase-catalyzed kinetic resolution of tiaprofenic acid in nonstandard HPLC organic solvents.
2008 Aug
Cholesterol-diaryl ketone stereoisomeric dyads as models for "clean" type I and type II photooxygenation mechanisms.
2008 Mar 7
The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery.
2008 Oct 31
Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.
2009
Systematic review of the management of canine osteoarthritis.
2009 Apr 4
Contact dermatitis due to topical drugs.
2009 Oct
Single dose oral tiaprofenic acid for acute postoperative pain in adults.
2009 Oct 7
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.
2009 Sep
Hemorrhagic cystitis: A challenge to the urologist.
2010 Apr
Enhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis.
2010 Dec 1
The effect of terpenes on percutaneous absorption of tiaprofenic acid gel.
2010 Nov
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Sample Use Guides

The recommended daily dose range for adults is 600 mg tiaprofen acid per day divided into 2 doses.
Route of Administration: Oral
In Vitro Use Guide
Human osteoarthritic cartilage was treated with therapeutic doses of tiaprofenic acid (26 micrograms/ml; 2.6 micrograms/ml) in order to test the effect of the drug on the proteoglycan metabolism (catabolism and synthesis) and chondrocyte ultrastructure. The drug suppresed the proteoglycan metabolism by 38%.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:30 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:30 GMT 2025
Record UNII
1LS1T6R34C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SURGAM
Preferred Name English
TIAPROFENIC ACID
EP   INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
TIAPROFEN
Brand Name English
Tiaprofenic acid [WHO-DD]
Common Name English
TIAPROFENATE
Common Name English
tiaprofenic acid [INN]
Common Name English
5-BENZOYL-.ALPHA.-METHYL-2-THIOPHENEACETIC ACID
Systematic Name English
TIAPROFENIC ACID [MI]
Common Name English
RU-15060
Code English
TIAPROFENIC ACID [MART.]
Common Name English
TIAPROFENIC ACID [JAN]
Common Name English
TIAPROFENIC ACID [EP IMPURITY]
Common Name English
TIAPROFENIC ACID [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QM01AE11
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
NCI_THESAURUS C257
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
WHO-ATC M01AE11
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C90908
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
RXCUI
618442
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
ALTERNATIVE
MERCK INDEX
m10847
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY Merck Index
FDA UNII
1LS1T6R34C
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID5023665
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
DRUG CENTRAL
2652
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
CHEBI
32221
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
EVMPD
SUB11011MIG
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
SMS_ID
100000091864
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
MESH
C021270
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
ECHA (EC/EINECS)
251-329-3
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
INN
3320
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
CAS
33005-95-7
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
DRUG BANK
DB01600
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
WIKIPEDIA
TIAPROFENIC ACID
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
RXCUI
38253
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
ChEMBL
CHEMBL365795
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
PUBCHEM
5468
Created by admin on Mon Mar 31 17:59:30 GMT 2025 , Edited by admin on Mon Mar 31 17:59:30 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY